Jefferson Shreve sold Bristol-Myers Squibb Company (NYSE: BMY)
Jefferson Shreve (R-IN), a U.S. Representative, has disclosed 1 trade in Bristol-Myers Squibb Company (BMY) since 2025, a single sale, worth an estimated $33K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Jefferson Shreve sold $15,001 - $50,000 of Bristol-Myers Squibb Company (NYSE: BMY) on May 12, 2025. Since that trade, BMY is up +37.51% against the S&P 500 up +26.56%, an outperformance of +10.95%.
Data updated
Jefferson Shreve's BMY trades vs the price
BMY is up +37.51% since Jefferson Shreve sold on May 12, 2025, versus +26.56% for the S&P 500.
Performance since this trade
All Jefferson Shreve BMY trades
Jefferson Shreve & BMY trading FAQ
Is it legal for Jefferson Shreve to trade Bristol-Myers Squibb Company (BMY) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Bristol-Myers Squibb Company (BMY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Jefferson Shreve sell BMY?
Jefferson Shreve disclosed a sale of $15,001 - $50,000 of Bristol-Myers Squibb Company (BMY) on May 12, 2025, according to public STOCK Act filings.
How has BMY performed since Jefferson Shreve's trade?
Since Jefferson Shreve sold BMY on May 12, 2025, the stock is up +37.51%, versus +26.56% for the S&P 500 over the same period, an outperformance of +10.95%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional BMY trades?
Quantellect tracks every disclosed congressional trade in Bristol-Myers Squibb Company (BMY) on the Bristol-Myers Squibb Company congressional trading page, which aggregates filings across all members of Congress.
Jefferson Shreve's BMY tradesAll congressional filings for Bristol-Myers Squibb CompanyJefferson Shreve's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.